US Patent Issued to Rutgers, The State University of New Jersey on Nov. 3 for "Modified kisspeptin receptor agonists for fatty liver disease" (New Jersey Inventors)

ALEXANDRIA, Va., Nov. 3 -- United States Patent no. 12,779,013, issued on Nov. 3, was assigned to Rutgers, The State University of New Jersey (New Brunswick, N.J.).

"Modified kisspeptin receptor agonists for fatty liver disease" was invented by M. Moshmi Bhattacharya Babwah (New Brunswick, N.J.), Andy Videsh Babwah (New Brunswick, N.J.), Sally Radovick (New Brunswick, N.J.) and Fredric E. Wondisford (New Brunswick, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This invention involves repurposing the use of TAK-448 in NAFLD or NASH. In this study, a diet-induced mouse model of NAFLD was used to demonstrate that a hepatic knock-out of Kiss1r promotes steatosis. Moreover, infusion of the KP analog (TAK-48...